Want to see ABEO full AI Analyst Report?
ABEO Stock Chart & Stats
$6.05
$0.08(1.32%)
At close: 4:00 PM EDT
$6.05
$0.08(1.32%)
Day’s Range― - ―
52-Week Range$4.00 - $7.54
Previous Close$6.13
Volume779.34K
Average Volume (3M)1.40M
Market Cap
$365.91M
Enterprise Value$108.56
Total Cash (Recent Filing)$168.27M
Total Debt (Recent Filing)$23.17M
Price to Earnings (P/E)5.0
Beta1.54
Next Earnings
Aug 13, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume1,191,231
30 Day Avg. Volume1,402,709
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.75Price Target Upside226.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$66.29M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Rebound & Gross MarginsSustained revenue recovery and a ~52% gross margin indicate early product-market fit and scalable unit economics for ZEVASKYN. Durable margin support helps absorb SG&A as volumes grow and underpins medium‑term operating leverage as QTC throughput and payer reimbursement stabilize.
Broad Payer CoverageNear‑universal commercial coverage materially reduces reimbursement risk and supports repeatable revenue streams. Durable payer acceptance accelerates referral uptake, shortens reimbursement cycles, and improves cash realization compared with therapies lacking published coverage policies.
Reliable Manufacturing & Clinical ExecutionConsistent manufacturing yield and short turnaround are structural advantages for a cell therapy launch, lowering per‑patient failure risk and inventory write‑offs. Reliable execution enhances physician confidence, payer trust and scalable throughput as more QTCs onboard over months.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flows require continued external financing to fund commercialization and pipeline activities. This structural cash burn limits runway and strategic optionality, raising dilution risk and constraining investment in center expansion absent sustained positive operating cash generation.
Earnings Quality DisconnectReported net income not matched by cash flow implies non‑cash items or timing effects driving profitability metrics. This weakens confidence in earnings sustainability and complicates forecasting of true operating performance, reducing reliability of reported profits for funding or strategic decisions.
Operational & Payer Timing VariabilityMulti‑month onboarding and insurance approval delays are structural frictions for commercial scale in autologous cell therapy. They slow patient throughput, make revenue timing unpredictable, and can postpone achievement of steady‑state economics even as demand and coverage exist.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics Inc’s price range in the past 12 months?
Abeona Therapeutics Inc lowest stock price was $4.00 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics Inc’s market cap?
Abeona Therapeutics Inc’s market cap is $365.91M.
When is Abeona Therapeutics Inc’s upcoming earnings report date?
Abeona Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 5 days.
How were Abeona Therapeutics Inc’s earnings last quarter?
Abeona Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.035.
Is Abeona Therapeutics Inc overvalued?
According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued.
Does Abeona Therapeutics Inc pay dividends?
Abeona Therapeutics Inc does not currently pay dividends.
What is Abeona Therapeutics Inc’s EPS estimate?
Abeona Therapeutics Inc’s EPS estimate is -0.23.
How many shares outstanding does Abeona Therapeutics Inc have?
Abeona Therapeutics Inc has 56,995,144 shares outstanding.
What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?
Abeona Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went up 0.528%.
Which hedge fund is a major shareholder of Abeona Therapeutics Inc?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (226.45% Upside)
$19.75 (226.45% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 40.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO Company Deck
ABEO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear early commercial momentum for ZEVASKYN (notable revenue acceleration, 95% published commercial coverage, growing QTC network and manufacturing success with no harvest failures) and meaningful pipeline advancement with the in-licensed PSMA SIR-T program. Offsetting these positives are elevated operating expenses (notably SG&A), a larger reported net loss driven partly by a $7M upfront license payment, a declining cash balance, and operational / payer timing risks (variable biopsy lead times and lengthy insurance approvals for out-of-state Medicaid). On balance, the positives — strong initial revenue growth, payer coverage, successful manufacturing outcomes and a targeted oncology asset with limited near-term spend — outweigh the near-term financial and operational challenges.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$19.75
▲(226.45% Upside)
Technical Analysis
Ownership Overview
6.30% Insiders
6.74% Mutual Funds
8.64% Other Institutional Investors
69.26% Public Companies and
Individual Investors